Immunophenotyping of residual tumors showed that TKI treatment with either sorafenib or lenvatinib led to reduced tumor-infiltrating CD8+ T cells and increased immunosuppressive CD4+Foxp3+ regulatory T cells (Treg) (Fig. 1D). This evidence concerns the gene FOXP3 and neoplasm.